Pharmacogenomics Companies

Illumina (ILMN) Acquired GRAIL, a leader in cancer detection through circulating tumor DNA (ctDNA), for $8 billion. This strengthens Illumina's position in personalized medicine and early cancer detection.

Invitae (NVTA) Acquired Counsyl, a company specializing in prenatal and genetic carrier testing, for $1.2 billion. This expands Invitae's reach in reproductive health and positions them as a key player in personalized medicine.

Numares Health Secured FDA clearance for their AXINON® LDL-p Test System, the first commercially available NMR test for measuring LDL-p (particle number), a more precise indicator of cardiovascular risk than traditional LDL-C.

Biogen (BIIB) Announced positive Phase 2b data for aducanumab, an Alzheimer's disease treatment targeting beta-amyloid plaques. This reignites hope for a potential breakthrough in this challenging disease.

Pacific Biosciences (PACB) Unveiled their Revio™ long-read sequencing technology, offering unprecedented accuracy and resolution for whole-genome sequencing. This has significant implications for pharmacogenomics research and personalized medicine.

Guardant Health (GH) Developed the Lunar-Dx test, which combines liquid biopsy and tissue testing to provide a more comprehensive picture of tumor mutations and potential treatment options. This personalized approach holds promise for improved cancer care.

List of Pharmacogenomics Key Companies in the Market

• 
  

  Myriad Genetics, Inc. (U.S.)

  
  


• 
  

  23andMe, Inc. (U.S.)

  
  


• 
  

  Pathway Genomics (U.S.)

  
  


• 
  

  GeneTech (U.S.)

  
  


• 
  

  Future Science Group (U.S.)

  
  


• 
  

  Teva Pharmaceutical Industries Ltd. (Israel)

  
  


• 
  

  Assurex Health, Inc. (U.S.)

  
  


• 
  

  Bristol-Myers Squibb Company

  
  


• 
  

  Hoffmann-La Roche Ltd.

  
  


• 
  

  Merck & Co., Inc.

  
  


• 
  

  Johnson & Johnson

  
  


• 
  

  Abbott Laboratories, Inc.